Cisplatin and its analogues in the treatment of advanced breast cancer: a review. by Smith, I. E. & Talbot, D. C.
Br. J. Cancer (1992), 65, 787 793
© Macmillan Press
Cisplatin and its analogues in the treatment of advanced breast cancer: a
review
I.E. Smith & D.C. Talbot
The Breast Unit, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK.
Cisplatin is one of the most active of currently available
cytotoxic agents and has efficacy against a wide range of
malignancies. More recently one of its analogues, carbo-
platin, has tended to replace cisplatin in the treatment of
some tumour types on the basis of equivalent efficacy and
significantly decreased nephrotoxicity and neurotoxicity
(Calvert et al., 1982; Smith et al., 1985; Wiltshaw, 1985).
Cis-dichloro-trans-dihydroxy bis (isopropylamine) platinum
(iv) (CHIP, Iproplatin), another analogue investigated in
parallel with carboplatin, likewise proved to be an active agent
(Sessa et al., 1988; van Glabbeke et al., 1988) but its develop-
ment was curtailed with the emergence of nephrotoxicity.
Despite its wide spectrum of clinical activity, cisplatin
initially made little impact in the treatment of metastatic
breast cancer. There were two main reasons for this. First,
early studies usually in heavily pre-treated patients suggested
little activity. Second, its toxicity spectrum, including severe
emesis and the need for in-patient intravenous hydration to
minimise nephrotoxicity, made it unattractive compared with
established simple out-patient regimens including CMF and
FAC in this area of palliative cancer medicine. Within the
last few years, however, data have emerged suggesting that
cisplatin when used as first-line chemotherapy may be much
more active than first thought against breast cancer.
This has stimulated a spate of further studies of cisplatin
and its analogues, both alone and in combination, in an
attempt to find more effective chemotherapy for this disease.
Cisplatin
Perhaps even more than for other cytotoxic drugs, the
activity of cisplatin in the treatment of advanced breast
cancer is dependent on whether or not patients have received
previous chemotherapy.
Single agent -previously treatedpatients
The first clinical breast cancer trials of single agent cisplatin
were carried out in the late 1970s in heavily pretreated
patients. Yap et al. (1978) found no responders in 26 patients
treated with either 100mgm-2 q 3-4 weekly or 20mgm-2
daily x 5, q 4 weekly. Ostrow et al. (1980) likewise reported
only two responses out of 17 pre-treated patients at a dose of
100 mg m2 every 3-4 weeks. Subsequent similar studies
continued to report few responders, in doses ranging from
60 mg m-2 every 3 weeks to 35 mgm-2 daily x 5 (175 mgm-2)
every 4 weeks (Forastiere et al., 1982; Martino et al., 1984;
Bajorin et al., 1987). These studies are summarised in Table I
which shows only ten responders out of 113 patients (overall
response rate 9%). There is the suggestion of a dose response
effect here and the relation of dose-intensity to response rate
was analysed by Sledge and Roth (1989) who found a positive
correlation: no responses were seen in patients treated at
<25mgm-2week-', compared with 7% at 25-33mgm-2
week-2 and 25% at > 33mgm-2 week- '.
Single agent cisplatin -previously untreatedpatients
The first study of cisplatin in breast cancer patients who had
not received previous chemotherapy was reported by Kolaric
and Roth (1983) with a dose of 30 mg m2 i.v. daily for 4
days every 3 weeks. Nineteen out of 35 patients responded
(54%) incuding 13 patients with CR. Median response dura-
tion was 5 months. More recently, these results were con-
firmed by Sledge et al. (1988) who treated 20 patients with
the same dose and schedule. None had received previous
chemotherapy for metastatic disease although eight had
received prior adjuvant chemotherapy. Nine of 19 evaluable
patients achieved partial remissions (47%). Response dura-
tion ranged from 2.5 to 17 months with a median of 5
months. Prior adjuvant therapy did not appear to influence
response to cisplatin: 3/8 patients receiving prior adjuvant
therapy responded compared with 6/11 patients who had not
received this treatment. Finally, in a small Czechoslovakian
study 5/12 (42%) of previously untreated patients treated
with an identical dose and schedule of cisplatin achieved an
objective response (Mechl, 1988).
These studies are also summarised in Tab-ieA which shows
that 33 out of 66 evaluable patients given high dose cisplatin
without prior chemotherapy for metastatic disease achieved a
response (overall response rate 50%). These results put cis-
platin among the most active agents yet developed in the
treatment of metastatic breast cancer.
This activity is bought at a price, however. Cisplatin at a
dose equivalent to 120 mgm2 q 4 weekly is a toxic treat-
ment by any standard. Nausea and vomiting are universal
and require intensive in-patient anti-emetic therapy, and
intravenous hydration is essential to decrease the risk of
nephrotoxicity. Even with these measures significant toxicity
remains: in their study Sledge et al. (1988) reported a rise in
serum creatinine sufficient to require dose reduction or dis-
continuation of therapy in three patients, clinically significant
neurotoxicity occurred in four patients (20%) and ototoxicity
in two (10%). This puts a major question mark over the role
of high dose cisplatin in this area of cancer medicine where
the main aim of treatment is palliation.
Because of this it would be of interest to know the extent
of the dose-response effect for cisplatin in previously un-
treated patients. A more moderate dose and schedule of
50-75 mg m-2 every 3 weeks is associated with markedly less
subjective and objective toxicity and it is possible that such
benefits could be achieved with only a small trade-off in
response rate. Single agent data here in previously untreated
patients are not available, although this dose range is fre-
quently used in combination studies described below. The
other approach is to investigate cisplatin analogues which
might have equivalent activity but less toxicity in the treat-
ment of metastatic breast cancer (see below).
Cisplatin in conventional dose combination chemotherapy:
second line treatment
There are now many studies in the literature using cisplatin
as part of combination chemotherapy in previously treated
patients and these are summarised in Table II. Some com-
binations include the commonly used cytotoxic agents against
advanced breast cancer (doxorubicin, methotrexate, SFU,
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Table I Single agent cisplatin
Previous
Reference chemotherapy Dose Response
Yap et al., 1978 Yes 20mgm-2 q d x 5 q 4 wk 0/14
100mgm-2 q 3-4 wk 0/12
Ostrow et al., 1980 Yes 100 mg m-2 q 3-4 wk 2/17
Forastiere et al., 1982 Yes 60mgm-2 q 3 wk 0/18
120mgm-2 q 3 wk 4/19
Martino et al., 1984 Yes 15mgm-2 q d x 5 q 4 wk 0/15
100-120mgm-2 q 4 wk 2/13
Bajorin et al., 1987 Yes 35 mgm-2 q d x 5 q 4 wk 2/5
Total 10/113
Kolaric & Roth, 1983 No 30mgm-2 q d x 4 q 3 wk 19/35
Mechl & Sopova, 1984 No 30mgm-2 q d x 4 q 3 wk 5/12
Sledge et al., 1988 No 30mgm-2 q dx4 q 3 wk 9/19
Total 33/66
Table II Combination cisplatin in previously treated patients
Concurrent No. Response Median response
Reference Dose Schedule treatment eval. rate (%) duration (mo)
Mechl & Sopkova, 1984 80mgm-2 q 4 wk C, A 6 17 -
Paridaens et al., 1985 lOOmgm-2 q 4 wk Vds 46 19 5
Cocconi et al., 1986 80mgm-2 q 3 wk E 30 17 4
Tinsley et al., 1986 20mgm-2 q dx5 q 3 wk E 42 17 2.5
Gonzalez et al., 1986 15mgm-2 q d x 5 F 16 68 6+
(frequency not given)
Cox et al., 1987 20mgm-' q d x 5 d q 3-6 wk E 11 37 6
Zaniboni et al., 1987 30mgm-2 d 1,3,5 q 4 wk C, Epi 11 0
Fornasiero et al., 1987 30mgm-2 d 1,3,5 q 3-4 wk C, A 45 45 7
Cox et al., 1989 20mgm-2 q dx 5 q 3-6 wk E 29 38
Hart et al., 1989 20mgm-2 q dx5 q 4 wk F, LV 11 9
Bitran et al., 1990 lOOmgm-2 q 4 wk CiF 24 50 4.9
Krook et al., 1990 45mgm-2 ci q dx2 q 4 wk E 44 25 4
Saphner et al., 1991 20-60mgm-2 q wk x 7 CiF, E 13 15 -
Khayat et al., 1991 35mgm-2 q d x 3 E, CiF, A, M 53 60 -
Bromberg et al., 1991 25mgm-2 ci q dx 3 q 3 wk E 17 35 2
Morere et al., 1991 10mg iai q dx6-13d q 4 wk B+Vbl 17 65 -
or M or F
Leong et al., 1991 5-20mgm-2 iv q dx5 q 4 wk F, LV 19 42 2
Abbreviations: A =doxorubicin;. B = bleomycin; C = cyclophosphamide; ci =continuous infusion; E=etoposide; Epi = epirubicin;
F = 5-fluorouracil; I = ifosfamide; iai = intraarterial infusion; LV = leucovorin; M = mitomycin-C; Vbl = vinblastine; Vds = vindesine.
cyclophosphamide, vinblastine, mitomycin C). Others include
agents not frequently used for the treatment of this disease
such as etoposide. The rationale for this approach is that the
combination of cisplatin and etoposide has been shown to be
active in other tumour types particularly small cell and non-
small cell lung cancer. These studies are all uncontrolled, and
often accrue only small numbers of patients. In many of the
combinations, response rates are low, but it is worth noting
that a few studies using cisplatin in combination with 5FU,
with or without other additional agents, achieve response
rates as high as 68% for second-line chemotherapy (Gonzalez
et al., 1986; Bitran et al., 1990; Khayat et al., 1991). This
combination justifies further investigation.
Cisplatin in conventional dose combination chemotherapy:first
line treatment
There is now a considerable literature on the role ofcisplatin
in combination chemotherapy in previously untreated
patients and this is summarised in Table III. Again, some
studies involve cisplatin in combination with conventional
anti-breast cancer chemotherapy and others use the agent in
combination with etoposide. Many of these studies are again
uncontrolled and involve small numbers of patients. The
overall trend suggests a higher response rate than for patients
who have received previous chemotherapy.
Within this group there are four randomised trials compar-
ing cisplatin combination chemotherapy with conventional
regimens. In the first, 72 patients were randomised to receive
either cyclophosphamide, doxorubicin and cisplatin (CAP) or
cyclophosphamide, methotrexate, 5FU, vincristine and pred-
nisolone (CMFVP) (Kolaric et al., 1984). CAP achieved a
significantly higher response rate of 75% compared with 44%
(P <0.01) for CMFVP but there was no significant difference
in response duration or overall survival. Toxic side-effects
were more pronounced with CAP, including in particular
myelosuppression, anaemia and vomiting. In this trial 5/11
(45%) CMFVP-resistant patients showed a second-line objec-
tive response to CAP. In the second trial, a similar CAP
protocol followed by maintenance cyclophosphamide, 5FU
and prednisolone was compared with cyclophosphamide,
5FU and prednisolone along in a randomised trial of 86
patients of whom only seven had had prior chemotherapy
(Creagen et al., 1984). CFP (CFP) alone was associated with
a response rate of 46%, a median time to progression of 9
months and a median survival of 18 months vs 49%, 6
months and 11 months respectively for CAP followed by
CFP. In addition to this trend towards worse survival, the
cisplatin combination was associated with a significant in-
crease in nausea and vomiting. In the third trial, CAP
achieved a response rate of 67% compared with 41% for the
conventional FAC regimen (5FU, doxorubicin, cyclophos-
phamide), again without significant difference in median re-CISPLATIN, CARBOPLATIN IN BREAST CANCER 789
sponse duration or survival (Kolaric et al., 1989). In the
fourth trial, an Italian group compared a novel combination
of cisplatin and etoposide with a standard CMF regimen
(Cocconi et al., 1991). Cisplatin and etoposide achieved a
response rate of 63% compared with 48% for CMF
(P = 0.08). There was no significant difference in time to
treatment progression, response duration or survival, but
haematological toxicity, nausea and vomiting were greater
with the cisplatin/etoposide combination.
The overall impression from these trials is that first-line
combination chemotherapy which included cisplatin may
achieve slightly higher response rates than conventional
schedules but with increased toxicity and without significant
benefit in terms of response duration.
Cisplatin in high dose chemotherapy
Cisplatin is hardly the ideal drug for dose escalation with
autologous bone marrow rescue (ABMR) because of its
important non-haematological toxicities. Nevertheless this
agent has been used in several high dose combination
schedules, summarised in Table IV.
In the first major study of its type, Eder et al. (1986)
treated 17 patients with high dose cisplatin 165 mg m-2,
cyclophosphamide 5.625g m-2 and BCNU 600 mg m-2 with
ABMR. Fourteen of 16 evaluable patients responded (88%),
including six complete responders (38%). Thirteen of these
patients had been previously treated. Median time to tumour
progression and median survival were however disappoint-
Table HI Combination cisplatin in previously untreated patients
Concurrent No. Response Median response
Reference Dose Schedule treatment eval. rate (%) duration (mo)
Mechl & Sopova, 1984 80mgm-2 q 4 wk C, A 6 83 6.3
Kolaric et al., 1984 20mgm-2 d 1,3,5, q 3-4 wk C, A 36 75 12+
Creagen et al., 1985 40mgm-2 q 4 wk C,A, F, P 45 49 6
Kolaric et al., 1986 20mgm-2 d 1,3,5 q 3-4 wk C, A 38 58 8+
Zaniboni et al., 1987 30mgm-2 d 1,3,5 q 4 wk C 10 70 6.2
Cocconi et al., 1991 100 mgm2 q 3 wk E 65 63 11
Roth et al., 1988 70mgm-2 q 4 wk Mtx, Vbl, A 38 66 5 +
Verusio et al., 1988 20mgm-2 q d x 3 q 3 wk C, E 20 70 9
Colozza et al., 1989 20mgm-2 d 1-3 q 3 wk C, A 33 64 11
Kudelka et al., 1989 70mgm-2 q 4 wk Mtx, Vbl, A, LV 34 91 -
Kolaric et al., 1989 30mgm-2 d 1,3,5 C, A 67 NS
Kolaric & Tomek, 1990 30mgm-2 d 1,3,5 C, Mtx, F, 45 82 12
Vc, P, A,
('alternating
CAP/CMFVP')
Langer et al., 1991 70mgm-2 q 4 wk Mtx, Vbl, A 29 86 5.5
Abbreviations: A = doxorubicin;. B = bleomycin; C=cyclophosphamide; ci = continuous infusion; E=etoposide; Epi = epirubicin; F = 5-fluorouracil; I = ifosfamide; iai = intraarterial infusion; LV = leucovorin; M = mitomycin-C; Mtx = methotrexate; P = prednisolone; Vbl = vinblastine; Vc = vincristine; Vds = vindesine.
Table IV High dose cisplatin with autologous bone marrow rescue
Previous Median
chemotherapy Overall response Treatment-
for metastatic Concurrent Eval. response duration related Reference disease Dose chemotherapy Pts. (%) CR (%) (months) deaths (%)
Eder et al., 1986 13 165 mgm-2 C 5.65 gm2 16 88 38 5 18
BCNU 600 mgm2
+ ABMR
Peters et al., 1988 None 165 mgm2 C 6.65 mgm-2 22 77 54 9 23
BCNU 600mgm2
or
Melphalan 40mg m-2
+ ABMR
Peters et al., 1990 None 165mgm-2 C 5.6mgm-2 35 - - 11
BCNU 600 mg m2 (adjuvant)
+ ABMR
Jones et al., 1990 None 55mgm2 q AFMtx induction - 39 97 64 - 20
d x 4 C 1.875 mgm-2q d x 3
BCNU 600 mg m 2
x 1 day +ABMR
Tenny et al., 1990 10 40mgm-2 C 25-50mgm-2 q dx4 7 100 43 43
q dx4 E 375-560mgm-2 q
or dx4+ABMR
Carboplatin
375 mgm2 q
d x 4
Huan et al., 1991 None 120-165 mgm2 Conventional 73 81 55 - not given
chemotherapy +
C 4.5-6 gm-2
E 750-1500 mgm-2
± ABMR
Gingrich et al., 1991 120-200mgm-2 E 1600-2600mgm-2 52 37 all CR - 10
C 160 mgm-2 ± Thiotepa
180-480 mgm-2
± RT + ABMR
E = etoposide; C = cyclophosphamide; AFMTX = doxorubicin, 5FU, methotrexate; ABMR = autologous bone marrow rescue.790 I.E. SMITH & D.C. TALBOT
ingly short at 5 months and 8 months respectively. There
were three treatment-related deaths (18%) and causes of
death included renal failure. Subsequently, Peters et al.
(1988) at Duke University reported a similar study in which
22 premenopausal patients with oestrogen receptor negative
disease were treated with an identical schedule except that
melphalan 40 mg m-2 was sometimes substituted for BCNU.
In contrast to the first study, none of these patients had
received previous chemotherapy for metastatic disease.
Seventeen (77%) achieved a response including 12 (54%)
complete responders. Median response duration was 9
months and median survival for all patients was 8 months.
Three patients acheived unmaintained remission beyond 16
months. Five patients (23%) had treatment-related deaths.
Other similarly designed studies so far involve patient
numbers too small to draw meaningful conclusions (e.g.
Tenny et al., 1990).
A second approach with high dose chemotherapy is to use
this as so-called consolidation after conventional induction
treatment. The Duke University group have also used this
approach with an induction schedule of doxorubicin, 5FU
and methotrexate followed by intensive consolidation
chemotherapy using cyclophosphamide 1.87gm2 daily x 3
days, cisplatin 55 mg m-2 x 4 days and BCNU 600 mgm-2 x
1 day (Jones et al., 1990). This approach achieved a 97%
response rate in 39 patients including 25 (64%) achieving a
complete remission. Eventually, however eight patients (28%)
died of treatment related toxicity. Using a similar approach,
the MD Anderson group has very recently reported an
overall response rate of 81% including 55% complete remis-
sions using cyclophosphamide 4.5-6g m-2, etoposide
750-1,500 mg m-2 and cisplatin 120-165 mg m-2 as con-
solidation following conventional induction chemotherapy
(Huan et al., 1991). However, a 74% objective response rate
including 30% CR were achieved with conventional therapy
alone. Mortality rate related to high dose therapy was not
given.
Finally, in a provocative study, Peters et al. (1990) have
reported preliminary results of high dose cisplatin as part of
adjuvant chemotherapy. In this study high risk patients with
early breast cancer and ten or more involved axillary nodes
were treated initially with four cycles of conventional cyclo-
phosphamide, doxorubicin and 5FU chemotherapy followed
by high dose cisplatin 165 mg m2, cyclophosphamide
5.6gm2 and carmustine 600mgm2 with ABMR. Four of
35 patients treated in this way died of treatment-related
complications (11%); it is otherwise too early to draw con-
clusions from this study. A randomised comparative trial is
now under way.
Carboplatin
Single agent -previously treatedpatients
Results with carboplatin in the treatment of advanced breast
cancer follow early experience with cisplatin: clinical activity
appears related to whether or not the patient has received
previous chemotherapy.
In the earliest carboplatin study, carried out by CALGB,
20 patients were treated with a 24 h infusion of either
320 mg m-2 if they were considered good risk, or 280 mg m-2
if they were considered poor risk based on previous therapy
with nitrosoureas, mitomycin-C or large volume radiotherapy
(Booth et al., 1985). Treatment was repeated every 28 days.
All patients had been heavily pre-treated with conventional
chemotherapy and had received a median of six previous
drugs. Fourteen patients were evaluable for response, but no
responses were seen.
More recently in a Spanish study, Martin et al. (1991)
reported 14 previously treated evaluable patients given carbo-
platin in a dose of 400 mg m-2 repeating 4 weekly. All but
one of these had previously received a doxorubicin-contain-
ing regimen, usually FAC; eight of these had only received
adjuvant chemotherapy. Again, no responses were seen.
We are currently carrying out a phase II study of single
agent carboplatin in advanced breast cancer, using a pharma-
cokinetically determined dose related to renal function
(Calvert et al., 1989). Our aim is to achieve an area under the
concentration vs time curve (AUC) of 7 mgml- min-'. So
far only one of eight previously treated patients have re-
sponded. Table V summarises these results and the overall
response rate is only one out of 36 (3%).
Single agent -previously untreatedpatients
Kolaric's group in Yugoslavia has recently followed up their
original cisplatin work with a study using carboplatin in 20
patients who had received no previous chemotherapy
(Kolaric & Vukas, 1990). This group attempted to give a
dose of 400mgm-2 every 3 weeks, rather than every 4
weeks. All patients were evaluable; there were two CRs and
two PRs giving a 20% overall response rate (95% confidence
limits 6-44%). Remission durations ranged from 2-8
months with a median of 4 months. The increased frequency
of scheduling was associated with a surprisingly modest
degree of short-term myelo-suppression. Eight patients had
leukopenia but only two grade 3/4; three patients had
thrombocytopenia but only one was grade 3/4. Longer term
myelosuppression was more of a problem however, and the
maximum number of cycles that could be given was five.
Seven out of 13 patients subsequently responded to conven-
tional combination CMFVP chemotherapy (54%).
In the second part of the Spanish study mentioned above,
21 previously untreated patients were given carboplatin
400 mg m2 q 4 weekly (Martin et al., 1991). Nineteen were
evaluable for response and of these one achieved a CR and
five a PR giving an overall response rate of 32% (13-57%).
Response durations ranged from 5 to 15 + months. Only
four patients were given six or more courses. Leukopenia and
thrombocytopenia were mild. Five out of ten patients subse-
quently responded to conventional FAC chemotherapy in-
cluding five out of eight failing to respond to carboplatin.
In a small joint Portugeuse-UK study reported by Carmo-
Periera et al. (1990) only two of 15 previously untreated
patients responded to carboplatin in a dose of 400 mgm-2
every 4 weeks. Finally, in our own on-going pharma-
cokinetically determined study nine out of 21 previously
untreated patients have so far responded.
These results are summarised in Table V. The overall
response rate in previously untreated patients is 21/75 (28%).
This suggests a lower response rate than for cisplatin, and if
this is real then it is surprising; in other tumour types carbo-
platin appears to have broadly similar efficacy to cisplatin
(Smith et al., 1985; Wiltshaw et al., 1985).
Carboplatin in combination chemotherapy
There are relatively few published studies of carboplatin in
conventional dosage as part of combination chemotherapy
and these are listed in Table VI. In the majority of these
carboplatin has been given with SFU in patients who have
already received prior chemotherapy, and response rates in
small series range from 25-44% (Fernandez-Hidalgo et al.,
1989; Allegra, 1989; Khayat et al., 1989). Carboplatin has
also been used in an unconventional regimen with etoposide
and ifosfamide, a combination that we have already found
highly active in small cell lung cancer (Smith et al., 1990). In
a group of 26 breast cancer patients described as being
refractory to chemotherapy a 42% response was achieved
(Fields et al., 1991). Meaningful conclusions about the role of
carboplatin in combination chemotherapy cannot be drawn
from the limited data in these studies.
Carboplatin in high dose combination chemotherapy with
autologous bone marrow rescue
Carboplatin is a much more appropriate drug than cisplatin
for use in high dose chemotherapy studies with AMBR; its
dose limiting toxicity is myelosuppression and we have foundCISPLATIN, CARBOPLATIN IN BREAST CANCER 791
Table V Carboplatin as single agent chemotherapy
Previous
Reference chemotherapy Dose Response
Booth et al., 1985 Yes 280-320mgm-2 q 4 wk 0/14
Martin et al., 1991 Yes 400mgm-2 q 4 wk 0/14
O'Brien et al., 1991 Yes AUC 7mg ml-' min' q 4 wk 1/8
Total 1/36 (3%)
Kolaric & Vukas, 1990 No 400 mgm-2 q 3 wk 4/20
Carmo-Periera et al., 1989 No 400mgm2 q 4 wk 2/15
Martin et al., 1991 No 400mgm-2 q 4 wk 6/19
O'Brien et al., 1991 No AUC 7mgml-'min-' q 4 wk 9/21
Total 21/75 (28%)
Table VI Carboplatin combination chemotherapy
Concurrent No. Response Median response
Reference Dose Schedule treatment eval. rate (%) duration (mo)
Field et al., 1991 200mgm 2 q dx2 q 4 wk I, E 26 42 -
Allegra et al., 1989 50-lOOmgm-2 q dx3 q 4 wk F, LV 18 44 6.3
Khayat et al., 1989 350mgm-2 ia q 4 wk F 4 25
Fernandez-Hidalgo 55mgm-2 3-5 d i.v. q 5 wk F 31 20 -
et al., 1989
E = etoposide; F = 5FU; I = ifosfamide; LV = leucovonn.
that a 4-fold dose escalation to 1,600 mg m2 is clinically
feasible (Gore et al., 1987). The Boston group who pioneered
high dose cisplatin chemotherapy have also carried out a
similar study using dose-escalations of high dose carboplatin
(400-1,000 mg m-2) with cyclophosphamide 6G m-2 and
thiotepa 500-720 mg m-2 (Eder et al., 1990). Sixteen
previously treated patients with metastatic breast cancer were
included in this study of whom 13 (81%) responded includ-
ing one CR. Twenty-seven patients altogether with different
tumour types were entered; severe mucositis and neurotoxi-
city were dose-limiting and there were two treatment-related
deaths (7%).
Other groups are now also substituting carboplatin for
cisplatin (e.g. Tenny et al., 1990) as part of high dose
chemotherapy for programmes in the treatment of breast
cancer. The problem here is the apparently lower response
rate of the analogue compared with the parent compound.
This highlights the need to find new cisplatin analogues with
the activity of the parent compound and the toxicity spect-
rum of carboplatin.
Iproplatin
Iproplatin is a second generation cisplatin derivative investi-
gated in parallel with carboplatin. Its further development
was curtailed by nephrotoxicity. During its period of clinical
study, iproplatin was investigated by three separate groups in
patients with advanced breast cancer, previously treated with
chemotherapy (Meisner et al., 1989; Casper et al., 1988;
Hortobagyi et al., 1987). Only seven patients out of 83
responded (8%). Details are given in Table VII.
Conclusions
Cisplatin has low activity as second-line treatment for
advanced breast cancer but data from three small studies
suggests that it is highly active as first-line treatment in
maximum conventional dosage of 120 mg m 2 every 3 weeks.
It would be reassuring to have this confirmed in larger
numbers of patients and it would also be helpful to have an
indication of response rate at lower dosage. In practice, it is
unlikely that such studies will be carried out. Cisplatin has
also been shown to be active in combination chemotherapy
but so far four randomised trials have failed to show survival
benefit over conventional treatment and its toxicity makes it
an awkward drug in this area of palliative medicine. It has
been incorporated in several high dose chemotherapy
regimens, but again its toxicity greatly limits its potential in
this area.
Carboplatin has a toxicity profile that makes it much more
appropriate for the treatment of breast cancer, both in con-
ventional and in high dosage. Unfortunately, results so far
suggest that its activity is lower than cisplatin in this disease,
even in previously untreated patients. More data are required
with carboplatin at higher dosage to justify its use in high
dose combination chemotherapy.
Finally, results with cisplatin as front-line therapy suggest
that breast cancer should be an important target tumour for
new cisplatin analogues.
Table VII Iproplatin (CHIP): single agent treatment
Previous
Reference chemotherapy Dose Response
Hortobagyi et al., 1987 Yes 270-300mgm-2 q 3 wk 4/30
Casper et al., 1988 Yes 275 mgm 2 q 4 wk 2/24
Meisner et al., 1989 Yes 45mgm-2 q d x 5 q 4 wk 1/29
Total 7/83 (8%)792 I.E. SMITH & D.C. TALBOT
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